PanopticAI’s Post

Dive into MICS News Volume 105 for cutting-edge insights on China's advancements. This month, explore the fusion of AI with medical care in Shenzhen, discover groundbreaking developments in elemental medicine, and learn about the rise of adult night schools. A must-read for professionals keen on the latest trends in technology, healthcare, and education. #Innovation #HealthTech #EducationTrends

Revolutionizing Healthcare, China’s AI Hospital Designed To Treat 3,000 Patients Daily China has unveiled the world’s first AI hospital, Agent Hospital, which promises to revolutionize healthcare by enabling robot doctors to treat up to 3,000 patients daily. Developed by Tsinghua University, this virtual facility aims to provide high-quality, affordable, and convenient healthcare, with AI doctors already demonstrating a 93.06% accuracy rate on the MedQA dataset. The AI hospital not only supports efficient patient care but also offers enhanced training for medical students, fostering the cultivation of highly-skilled doctors. Additionally, the AI system’s ability to predict and manage the spread of infectious diseases marks a significant advancement in public health management. As the AI hospital prepares for operational readiness by late 2024, it symbolizes a groundbreaking shift towards AI-driven medical care, offering substantial benefits while addressing critical challenges in technological validation and AI-human collaboration. #AI #China #AIHealthcare #DigitalTransformation #MedicalInnovation #FutureOfMedicine #HealthTech https://lnkd.in/gaSngNT7

Presenting biomistral-7b-synthetic-ehr: An Advanced LORA Adaptation of BioMistal-7B Data Collections Include: - health_facts - An Artificial Dataset Inspired by MIMIC-IV-Notes (validated) - EHR Public Data Collected and Reformatted - Additional Resources in the Lifescience Sector This model has been comprehensively fine-tuned on a Mac utilizing the MLX framework! 📌 Access the Model Here: in 👇 https://lnkd.in/dxHm4Zsu Collaborations are ongoing with various researchers and medical professionals to incorporate additional specialized datasets in areas of healthcare domain. After evaluating numerous foundational models for fine-tuning, biomistral demonstrated superior performance! **Will write a detailed blog on this!

I will be speaking at the Global Health Exhibition - ملتقى الصحة العالمي on Tuesday, October 22, 2024, at 10:45 AM Digital Health Forum stage. I’ll be sharing insights on the SFDA’s regulatory approach to AI-enabled medical devices, covering key topics such as: - Determining when AI technologies are classified as medical devices. - AI-enabled medical device risk classification criteria. - Key processes in the product lifecycle to ensure safety and effectiveness of AI-enabled devices. Looking forward to engaging with industry leaders and professionals on the future of AI in healthcare. #GlobalHealth #AI #MedicalDevices #DigitalHealth #Regulation #Innovation

Seeing clinical trials in a whole new light. Imagine capturing every crucial moment of a clinical trial with precision. At AnzuMedical, we're making this possible through the integration of video, audio, and image capture. This innovative approach not only enhances the accuracy of endpoint identification but also sets new standards for reliability in evaluations. Think of the possibilities when technology empowers you to monitor each step of a clinical trial with meticulous attention to detail. By harnessing multimedia, Anzu Medical offers a clear, comprehensive view of patient progress, ushering in a new era of standardization for study evaluations. Our commitment to HIPAA compliance ensures the utmost security and integrity, blending innovation with the highest standards of privacy. In a rapidly evolving scientific landscape, staying ahead means embracing technological advancements that transform research methodologies. Explore how AnzuMedical is shaping the future of medical research by providing tools for more precise and efficient clinical evaluations. Together, let's navigate this new frontier in healthcare innovation. #clinicaltrials #clinicalresearch #clinicaldata #mediacapture

The definition of AI. The kind post below about our recent Hardian Health Tech Summit contained a question about what people think of the definition of AI from the #EUAIact. Good question. The definition of AI from Art. 1(1) of the EU AI Act that became EU law on 1st August 2024: ‘AI system’ means a machine-based system that is designed to operate with varying levels of autonomy and that may exhibit adaptiveness after deployment, and that, for explicit or implicit objectives, infers, from the input it receives, how to generate outputs such as predictions, content, recommendations, or decisions that can influence physical or virtual environments; A different definition, this time from §940(3) of the USA's National Artificial Intelligence Initiative Act (NAIIA) 2020 that became US law on 1st January 2021: The term “artificial intelligence” means a machine-based system that can, for a given set of human-defined objectives, make predictions, recommendations or decisions influencing real or virtual environments. Artificial intelligence systems use machine and human-based inputs to— (A) perceive real and virtual environments; (B) abstract such perceptions into models through analysis in an automated manner; and (C) use model inference to formulate options for information or action. The OECD has a definition also, adopted by them on 22nd May 2019: An AI system is a machine-based system that, for explicit or implicit objectives, infers, from the input it receives, how to generate outputs such as predictions, content, recommendations, or decisions that can influence physical or virtual environments. Different AI systems vary in their levels of autonomy and adaptiveness after deployment. I'm sure there are more e.g. the UK ICO's (Information Commissioner's Office). The key themes, for me, are inference and perception. It might be tempting to overuse or misuse the notions of inference or perception for marketing, but the EU AI Act's Recital no. 12 has for me the key points for valid use of the term AI "... the definition should be based on key characteristics of AI systems that distinguish it from simpler traditional software systems or programming approaches and should not cover systems that are based on the rules defined solely by natural persons to automatically execute operations. A key characteristic of AI systems is their capability to infer..." Comments, please...

The U.S. FDA announces technical experts and industry representatives for its Digital Health Advisory Committee (DHAC) ⚖️The committee consists of 9 voting members with medical/academic experience plus digital health expertise, alongside 18 private sector leaders from Pharma, Medtech, and Venture representing industry interests. ⚖️ The panel will advise the FDA on digital health technologies, including AI/ML, virtual reality, wearables, digital therapeutics, and remote patient monitoring, with its first meeting in November focused on generative AI in medical devices. ⚖️ DHAC will also address issues like decentralized clinical trials, patient-generated health data, real-world data, real-world evidence, and cybersecurity. ⚖️ The committee will identify risks, barriers, and unintended consequences of FDA policies on digital health tech and advise the FDA on its use in clinical trials and postmarket studies. 💬It’s like the World Series of Digital Health - with only US based players allowed! Digital health is an interconnected and borderless field yet all 9 voting members are U.S. based same for 17/18 of the extended team (the exception is in Ireland but was previously U.S. based) 💬 A prime focus on the U.S. makes sense but this skewed composition is a missed opportunity and will likely limit the boards ability to exchange and assimilate global best practices and approaches. Increasing regional diversity would definitely enhance the boards ability to address the challenges and opportunities that lie ahead 👇Link to relevant articles in comments below #digitalhealth #ai #dtx #fda

Revolutionizing Research: The Benefits of Decentralized Clinical Trials Discover how decentralized clinical trials are transforming the landscape of clinical research. By leveraging digital technologies, these trials increase patient participation, enhance data quality, and reduce costs. Learn more about the future of patient-centric research in our latest blog! #ClinicalTrials #DecentralizedResearch #PatientCentric

HealthTech Ireland CEO Susan Treacy BSc., M.Med.Sc., PG Dip. reports from the MedTech Conference (#MTC24) in Toronto, where the sentiment throughout was optimistic and leaders agreed that it’s an exciting time to be in healthcare, as the potential for innovation and improvement seems limitless. Regulation of data and #AI was a hot topic, and one notable session featured NVIDIA’s David Niewolny, who spoke from another regulatory perspective, proposing the concept of digital twins and virtual testing environments as a way to improve AI systems in healthcare. #ehealth #healthit #digitalhealth #PulseIT

Exciting news ahead! According to Olivier Barberan, Director of Translational Medicines Solutions at Elsevier, we might soon see digital twins simulating the entire human body within the next decade. In an insightful interview with The Medicine Maker, Barberan delved into the potential of digital twins in medical practice and their various applications. While the idea of full-body digital twins sounds incredible, Barberan highlights the current challenges, particularly the need for vast amounts of high-quality data. Despite this hurdle, digital twins are already proving their worth in specific areas like drug adoption. The possibilities that digital twins offer in healthcare are endless. From simulating ailments to understanding bodily functions, they're poised to revolutionise medicine as we know it. You can read more here... https://bit.ly/44rkgAC